Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 13Recruiting 7Not yet recruiting 4Active not recruiting 3Unknown 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Large B-Cell, Diffuse 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Abiraterone Acetate 1

Interventions

Cyclophosphamide 10Rituximab 9polatuzumab vedotin 6Prednisone 6Doxorubicin 6Vincristine 5zanubrutinib 4glofitamab 4Prednisolone 4Lenalidomide 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Lisaftoclax 3tafasitamab 2obinutuzumab 2fludarabine 2Radiotherapy 2R-CHOP protocol 2Observation 2venetoclax 1sintilimab 1resiniferatoxin 1penpulimab 1pegfilgrastim 1orelabrutinib 1loncastuximab tesirine 1duvelisib 1acalabrutinib 1Vancomycin 1Therapeutics 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Large B-Cell, Diffuse × Prednisolone × Clear all
NCT07588698 2026-05-15

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

University of California, San Francisco

Phase 2 Not yet recruiting
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07035379 2025-08-22

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL

Zhejiang Teruisi Pharmaceutical Inc.

Phase 1/2 Not yet recruiting
66 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05990985 2023-08-18

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

The First Hospital of Jilin University

Phase NA Not yet recruiting
20 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05280626 2022-03-15

First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2 Not yet recruiting
100 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡